William P. McGuire

16.1k total citations · 6 hit papers
159 papers, 11.9k citations indexed

About

William P. McGuire is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, William P. McGuire has authored 159 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Reproductive Medicine, 63 papers in Oncology and 33 papers in Surgery. Recurrent topics in William P. McGuire's work include Ovarian cancer diagnosis and treatment (80 papers), Endometrial and Cervical Cancer Treatments (29 papers) and Cancer Treatment and Pharmacology (26 papers). William P. McGuire is often cited by papers focused on Ovarian cancer diagnosis and treatment (80 papers), Endometrial and Cervical Cancer Treatments (29 papers) and Cancer Treatment and Pharmacology (26 papers). William P. McGuire collaborates with scholars based in United States, United Kingdom and Australia. William P. McGuire's co-authors include Mark F. Brady, William J. Hoskins, Katherine Y. Look, Daniel L. Clarke‐Pearson, Martin Davidson, Paul R. Kucera, Edward E. Partridge, Robert C. Young, Robert F. Ozols and Eric K. Rowinsky and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

William P. McGuire

155 papers receiving 11.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

1996 2.3k citations William P. McGuire, William J. Hoskins et al. profile →
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response

1977 963 citations William P. McGuire et al. profile →
Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms

1989 897 citations William P. McGuire et al. profile →
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

2007 663 citations Robert F. Ozols, Peter G. Rose et al. Journal of Clinical Oncology profile →
Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

2007 574 citations Ursula A. Matulonis, Richard T. Penson et al. Journal of Clinical Oncology profile →
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

2009 500 citations Michael A. Bookman, Mark F. Brady et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by William P. McGuire

Since Specialization

Citations

This map shows the geographic impact of William P. McGuire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William P. McGuire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William P. McGuire more than expected).

Fields of papers citing papers by William P. McGuire

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William P. McGuire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William P. McGuire. The network helps show where William P. McGuire may publish in the future.

Co-authorship network of co-authors of William P. McGuire

This figure shows the co-authorship network connecting the top 25 collaborators of William P. McGuire. A scholar is included among the top collaborators of William P. McGuire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William P. McGuire. William P. McGuire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: A gynecologic oncology group study 2011 ·Gynecologic Oncology ·John Farley, Leia M. Smith, Kathleen M. Darcy, Mark F. Brady, Jeffrey A. Bell, William P. McGuire, Michael J. Birrer	7
2	Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study 2010 ·Gynecologic Oncology ·Jean Hurteau, Mark F. Brady, Kathleen M. Darcy, William P. McGuire, Pamela Edmonds, Michael L. Pearl, (unknown), Krishnansu S. Tewari, Robert S. Mannel, Kristine Zanotti, Doris M. Benbrook	56
3	Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup breakdown → 2009 ·Journal of Clinical Oncology ·Michael A. Bookman, Mark F. Brady, William P. McGuire, Peter Harper, David S. Alberts, Michael Friedländer, Nicoletta Colombo, Jeffrey M. Fowler, Peter A. Argenta, Koen De Geest, David G. Mutch, Robert A. Burger, Ann Marie Swart, Edward L. Trimble, (unknown), Lawrence M. Roth	500
4	A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer 2005 ·Gynecologic Oncology ·Michael V. Seiden, Alan N. Gordon, Diane C. Bodurka, Ursula A. Matulonis, Richard T. Penson, Eddie Reed, (unknown), (unknown), Michael Cullen, William P. McGuire	23
5	A Phase I Trial of Prolonged Oral Etoposide and Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study 2002 ·Gynecologic Oncology ·Peter G. Rose, Michael Rodriguez, Joan L. Walker, Benjamin E. Greer, Nancy Fusco, William P. McGuire	9
6	Phase I Trial of Paclitaxel and Etoposide for Recurrent Ovarian Carcinoma 2000 ·American Journal of Clinical Oncology ·Gini F. Fleming, Bruce J. Roth, Sharyn D. Baker, Gregory P. Sutton, Katherine Y. Look, Franco M. Muggia, Paula M. Fracasso, William P. McGuire	2
7	ICON2 trial (multiple letter) [1] 1999 ·The Lancet ·Martine Piccart, William P. McGuire, Martin Gore, (unknown), Valter Torri, Nicoletta Colombo, (unknown), Josie Sandercock	0
8	Pancreatic Polypeptide Hypersecretion Associated with a Neuroendocrine Carcinoma of the Gallbladder 1999 ·The American Journal of the Medical Sciences ·(unknown), Lewis S. Blevins, Anthony A. Gal, William P. McGuire	5
9	The Gynecologic Oncology Group experience in ovarian cancer 1999 ·Annals of Oncology ·William P. McGuire, Mark F. Brady, Robert F. Ozols	20
10	High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors 1998 ·Current Problems in Cancer ·William P. McGuire	19
11	Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. 1997 ·Journal of Clinical Oncology ·William P. McGuire, A. I. Neugut, (unknown), J.J. Doyle, Christopher M. Dezii	41
12	Cyclophosphamide and Cisplatin Compared With Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer 1996 ·Obstetrical & Gynecological Survey ·William P. McGuire, William J. Hoskins, Mark F. Brady, Paul R. Kucera, Edward E. Partridge, Katherine Y. Look, Daniel L. Clarke‐Pearson, Martin Davidson	38
13	Paclitaxel in cancer treatment 1995 ·M. Dekker eBooks ·William P. McGuire, Eric K. Rowinsky	37
14	Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine 1994 ·Cancer ·(unknown), Steven D. Averbuch, Douglas W. Ball, A de Bustros, Stephen B. Baylin, William P. McGuire	89
15	Phase II Study of Ifosfamide and Mesna in Nonsquamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study 1993 ·Gynecologic Oncology ·Gregory P. Sutton, John A. Blessing, Philip J. DiSaia, William P. McGuire	29
16	Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. 1992 ·Journal of Clinical Oncology ·Eric K. Rowinsky, L B Grochow, Carolyn B. Hendricks, David S. Ettinger, Arlene A. Forastiere, (unknown), William P. McGuire, S E Sartorius, Barbara G. Lubejko, Scott H. Kaufmann	302
17	Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferon 1992 ·Gynecologic Oncology ·Maurie Markman, Jonathan S. Berek, John A. Blessing, William P. McGuire, Jeffrey G. Bell, Howard D. Homesley	39
18	Synchronous mature teratomas of the ovary and liver: A case presenting 11 years following chemotherapy for immature teratoma 1992 ·Gynecologic Oncology ·Carlos Caldas, James V. Sitzmann, Cornelia L. Trimble, William P. McGuire	28
19	Phase II study of esorubicin (4′-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study 1989 ·Investigational New Drugs ·William P. McGuire, John A. Blessing, Edgardo Yordan, Jackson B. Beecham	8
20	A Phase II study of CHIP in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study) 1986 ·Investigational New Drugs ·William P. McGuire, John A. Blessing, Kenneth D. Hatch, Philip J. DiSaia	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact